Similarly, activated CD4+ T cells secrete IFNγ + EVs to enhance STING activation in tumor-associated macrophages, reprogramming them toward a pro-inflammatory phenotype and eventually amplifying the efficacy of STING-based cancer immunotherapies [20]. The gene discussed is STING1; the disease is cancer.